Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: Pathophysiological aspects

Hormone Molecular Biology and Clinical Investigation

Volumn 17, Issue 2, 2014, Pages 79-87

  Berg, Gabriela ^a   Schreier, Laura ^a   Miksztowicz, Veronica ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Adipose tissue; Insulin resistance; Matrix metalloproteinases; Sex hormones

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; LEPTIN; MATRIX METALLOPROTEINASE; SEX HORMONE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADIPOGENESIS; ADIPOSE TISSUE; ANGIOGENESIS; CARDIOMETABOLIC RISK; EXTRACELLULAR MATRIX; HORMONE SUBSTITUTION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; HEART MUSCLE; HUMAN; METABOLISM; RISK FACTOR;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; GONADAL STEROID HORMONES; HUMANS; LEPTIN; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; METABOLIC SYNDROME X; MYOCARDIUM; OBESITY; RISK FACTORS;

EID: 84928649724     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2013-0069     Document Type: Review

References (83)

1. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000;14:2123-33.
2. Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006;312:608-22.
3. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007;17:253-8.
4. Lijnen HR. Murine models of obesity and hormonal therapy. Thromb Res 2011;127:S17-20.
5. Després JP. Abdominal obesity and cardiovascular disease: is inflammation the missing link? Can J Cardiol 2012;28:642-52.
6. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009;58:718e25.
7. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008;37:635-46.
8. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73.
9. Borkakoti N. Structural studies of matrix metalloproteinases. J Mol Med 2000;78:261-8.
10. Lijnen HR. Angiogenesis and obesity. Cardiovasc Res 2008;78:286-93.
11. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1-31.
12. de Nooijer R, Verkleij CJ, von der Thüsen JH, Jukema JW, van der Wall EE, van Berkel TJ, Baker AH, Biessen EA. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006;26:340-6.
13. Choudhary S, Higgins CL, Chen IY, Reardon M, Lawrie G, Vick GW III, Karmonik C, Via DP, Morrisett JD. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler Thromb Vasc Biol 2006;26:2351-8.
14. Nagase H. Metalloproteases. Curr Protoc Protein Sci 2011;Chapter 21(Unit 21.4):1-13.
15. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
16. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27.
17. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002;288:2709-16.
18. Miksztowicz V, Muzzio ML, Royer M, Prada M, Wikinski R, Schreier L, Berg G. Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. Metabolism 2008;57:1493-6.
19. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R, Tavella M, Schreier L, Berg GA. Metalloproteases 2 and 9, Lp-PLA and lipoprotein profile in coronary patients. Arch Med Res 2009;40:48-53.
20. Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009;403:173-7.
21. Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase- 8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta 2007;379:48-52.
22. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 2007;5:265-82.
23. Lijnen HR, Maquoi E, Demeulemeester D, Van Hoef B, Collen D. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost 2002;88:345-53.
24. Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002;51:1093-101.
25. Christiaens V, Lijnen HR. Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue. Arch Physiol Biochem 2006;112:254-9.
26. Miksztowicz V, Morales C, Zago V, Friedman S, Schreier L, Berg G. Effect of insulin-resistance on circulating and adipose tissue MMP-2 and MMP-9 activity in rats fed a sucrose-rich diet. Nutr Metab Cardiovasc Dis 2014;24:294-300.
27. Gummesson A, Hagg D, Olson FJ, Hulthe J, Carlsson LM, Fagerberg B. Adipose tissue is not an important source for matrix metalloproteinase-9 in the circulation. Scand J Clin Lab Invest 2009;69:636e42.
28. Van Hul M, Piccard H, Lijnen HR. Gelatinase B (MMP-9) deficiency does not affect murine adipose tissue development. Thromb Haemost 2010;104:165-71.
29. Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008;15:219-24.
30. Pendás AM, Folgueras AR, Llano E, Caterina J, Frerard F, Rodríguez F, Astudillo A, Noël A, Birkedal-Hansen H, López-Otín C. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol 2004;24:5304-13.
31. Maquoi E, Demeulemeester D, Voros G, Collen D, Lijnen HR. Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation. Thromb Haemost 2003;89:696-704.
32. Lijnen HR, Van HB, Frederix L, Rio MC, Collen D. Adipocyte hypertrophy in stromelysin-3 deficient mice with nutritionally induced obesity. Thromb Haemost 2002;87:530-5.
33. Chun TH, Inoue M, Morisaki H, Yamanaka I, Miyamoto Y, Okamura T, Sato-Kusubata K, Weiss SJ. Genetic link between obesity and MMP14-dependent adipogenic collagen turnover. Diabetes 2010;59:2484-94.
34. Christiaens V, Scroyen I, Lijnen HR. Role of proteolysis in development of murine adipose tissue. Thromb Haemost 2008;99:290-4.
35. Van Hul M, Lijnen HR. A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 2008;6:1198-206.
36. Van Hul M, Lijnen HR. Matrix metalloproteinase inhibition impairs murine adipose tissue development independently of leptin. Endocr J 2011;58:101-7.
37. Van Hul M, Bauters D, Himmelreich U, Kindt N, Noppen B, Vanhove M, Lijnen HR. Effect of gelatinase inhibition on adipogenesis and adipose tissue development. Clin Exp Pharmacol Physiol 2012;39:49-56.
38. Boden G, Song W, Pashko L, Kresge K. In vivo effects of insulin and free fatty acids on matrix metalloproteinases in rat aorta. Diabetes 2008;57:476-83.
39. Boden G, Song W, Kresge K, Mozzoli M, Cheung P. Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors. Am J Physiol Endocrinol Metab 2008;295:E692-7.
40. Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013;227:216-21.
41. Sweeney G. Leptin signaling. Cell Signal 2002;14:655-63.
42. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HS. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001;33:95-102.
43. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001;47:141-50.
44. Li L, Mamputu JC, Wiernsperger N, Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 2005;54:2227-34.
45. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 2005;69:716-25.
46. Schram K, Wong MM, Palanivel R, No EK, Dixon IM, Sweeney G. Increased expression and cell surface localization of MT1-MMP plays a role in stimulation of MMP-2 activity by leptin in neonatal rat cardiac myofibroblasts. J Mol Cell Cardiol 2008;44:874-81.
47. Moon HS, Lee HG, Seo JH, Chung CS, Guo DD, Kim TG, Choi YJ, Cho CS. Leptin-induced matrix metalloproteinase-2 secretion is suppressed by trans-10,cis-12 conjugated linoleic acid. Biochem Biophys Res Commun 2007;356:955-6.
48. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004;89:3872-8.
49. Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 2012;94:2143-9.
50. Yuji Matsuzawa. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005;6:7-14.
51. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002;105:2893-8.
52. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-9.
53. Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Randazzo S, Cicero AF. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 2009;32:E124-32.
54. Cheng M, Hashmi S, Mao X, Zeng QT. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 2008;24:385-90.
55. Hwang JJ, Yang WS, Chiang FT, Chen MF, Lin HJ, Huang PJ, Hsu SH, Lai SK, Wu YW. Association of circulating matrix metalloproteinase- 1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis 2009;204:293-7.
56. Tong KM, Chen CP, Huang KC, Shieh DC, Cheng HC, Tzeng CY, Chen KH, Chiu YC, Tang CH. Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem 2011;112:1431-40.
57. Wu X, Yan Q, Zhang Z, Du G, Wan X. Acrp30 inhibits leptininduced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. Oncol Rep 2012;27:1488-96.
58. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001;63:165-92.
59. Davis KE, D Neinast M, Sun K, M Skiles W, D Bills J, A Zehr J, Zeve D, D Hahner L, W Cox D, M Gent L, Xu Y, V Wang Z, A Khan S, Clegg DJ. The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis. Mol Metab 2013;2:227-42.
60. Mesch VR, Boero LE, Siseles NO, Royer M, Prada M, Sayegh F, Schreier L, Benencia HJ, Berg GA. Metabolic syndrome throughout the menopausal transition: influence of age and menopausal status. Climacteric 2006;9:40-8.
61. Dubey RK, Imthurn B, Zacharia LC, Jackson EK. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 2004;44:789-95.
62. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 2004;286:R233-49.
63. Smiley DA, Khalil RA. Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem 2009;16:1863-87.
64. Miksztowicz V, Siseles N, Fernandez Machulsky N, Schreier L, Berg G. Increase in MMP-2 activity in overweight and obese women is associated with menopausal status. Climacteric 2012;15:602-6.
65. Uzui H, Sinha SK, Rajavashisth TB. 17?-Estradiol inhibits oxidized low-density lipoprotein-induced increase in matrix metalloproteinase-9 expression in human macrophages. J Invest Med 2011;59:1104-8.
66. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
67. Lewandowski KC, Komorowski J, Mikhalidis DP, Bienkiewicz M, Tan BK, O'Callaghan CJ, Lewinski A, Prelevic G, Randeva HS. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006;91:3123-30.
68. Grandas OH, Mountain DJ, Kirkpatrick SS, Rudrapatna VS, Cassada DC, Stevens SL, Freeman MB, Goldman MH. Effect of hormones on matrix metalloproteinases gene regulation in human aortic smooth muscle cells. J Surg Res 2008;148:94-9.
69. Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, Barrett-Connor E, Reuben DB. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 2006;185:347-52.
70. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44.
71. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc 2007;297:1465-77.
72. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-50.
73. Karas R, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med 2003;10:8-12.
74. Pustovrh MC, Jawerbaum A, Capobianco E, White V, Martínez N, López-Costa JJ, González E. Oxidative stress promotes the increase of matrix metalloproteinases-2 and -9 activities in the feto-placental unit of diabetic rats. Free Radic Res 2005;39:1285-93.
75. Pustovrh MC, Jawerbaum A, White V, Capobianco E, Higa R, Martínez N, López-Costa JJ, González E. The role of nitric oxide on matrix metalloproteinase 2 (MMP2) and MMP9 in placenta and fetus from diabetic rats. Reproduction 2007;134:605-13.
76. Capobianco E, White V, Sosa M, Di Marco I, Basualdo MN, Faingold MC, Jawerbaum A. Regulation of matrix metalloproteinases 2 and 9 activities by peroxynitrites in term placentas from type 2 diabetic patients. Reprod Sci 2012;19:814-22.
77. Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM, Randeva HS. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1173-7.
78. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-40.
79. Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res 2009;21:24-36.
80. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002;87:3632.
81. Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 2001;103:1382.
82. Tharp DL, Masseau I, Ivey J, Ganjam VK, Bowles DK. Endogenous testosterone attenuates neointima formation after moderate coronary balloon injury in male swine. Cardiovasc Res 2009;82:152.
83. Mountain DJ, Freeman BM, Kirkpatrick SS, Beddies JW, Arnold JD, Freeman MB, Goldman MH, Stevens SL, Klein FA, Grandas OH. Androgens regulate MMPs and the cellular processes of intimal hyperplasia. J Surg Res 2013;184:619-27.